Skip to content

Maxillary Sinus Floor Augmentation With Bioss® and Enamel Matrix Derivative: Evaluation of Osteogenic Properties

Maxillary Sinus Floor Augmentation With Bioss® and Enamel Matrix Derivative: Evaluation of Osteogenic Properties

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01870960
Acronym
EMDOGAIM
Enrollment
7
Registered
2013-06-06
Start date
2014-06-06
Completion date
2017-04-12
Last updated
2023-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patient Who is Requiring Bilateral Sinus Floor Elevation and Necessity of Dental Surgery

Brief summary

The main problem of using xenogenic bone in sinus floor elevation is the slow rate of absorption, which gives the percentages of vital bone low (20 to 30% depending on the study) in which the dental implant will be positioned However, osseointegration of the implant can be achieved only in vital bone. Enamel Matrix Derivative, through their angiogenic and osteogenic properties known, could promote bone healing during surgery sinus floor elevation by increasing the percentage of vital bone reformed, when added to xenografts.

Interventions

OTHER7 patients will be recuting to received EMDOGAIM in left side
OTHER7 patients will be recuting to received EMDOGAIM in right side

Sponsors

Centre Hospitalier Universitaire de Nice
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
45 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients \> 45 years, postmenopausal women (ie with amenorrhea for more than a year). * Subject requiring bilateral sinus floor elevation, in order to place two implants in grafted side. * patients smoking less than 10 cigarettes per day * patients having read and understood the information note on the study and signed the informed consent form. * patients affiliated to the social security system.

Exclusion criteria

* Patient with absolute contra-indication for dental surgery: valvular heart disease at risk of infectious endocarditis, recent myocardal (≤ 12 months), organ transplants, recent placement of a coronary stent (≤ 12 months), transient ischemic attacks recurrent, cardiovascular instability, uncontrolled epilepsy, rheumatic fever. * Patient with metabolic bone disease (Paget's disease, osteomalacia, osteogenesis imperfecta) * Patient with an ASA score ≥ 3. * Patient with absolute contra-indication to dental surgery * Patient with severe hematologic disease * Patient with I or type II diabetes * Patients with previous or current acute illness or severe chronic cardiovascular, renal, hepatic, gastrointestinal, allergic, endocrine, neuro-psychiatric, considered by the investigator to be incompatible with the conduct of the study. * Patients treated with retinoids, oral bisphosphonates, oral anticoagulants or anticonvulsants. * Patient have or have had cancer of the upper aerodigestive tract treated by radiotherapy. * Patient taking a steroidal or non-steroidal anti-inflammatory, anti-cancer or immunosuppressive chemotherapy in the last 6 months. * Patient monitoring considered difficult by the investigator. * Patient with poor oral hygiene incompatible with oral surgery. * Patients with periodontal disease unstabilized * Patient with oral dermatitis or adverse occlusion. * Patient with an acute or chronic infection of the surgical site (osteomyelitis). * Patient with a known allergy to collagen * Patient with autoimmune disease * Patient with a linguistic or mental incapacity to understand information * Patient younger than 45 years old * Patient trust under curatorship or judicial protection * Patients aged over 45 premenopausal. * Patient participating in another clinical study.

Design outcomes

Primary

MeasureTime frame
Percentage of vital bone obtained within the grafted siteevaluated six month after dental surgery

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026